Form 8-K PLIANT THERAPEUTICS, For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
August 8, 2024 9:30 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $32.00 price target on Pliant Therapeutics (NASDAQ: PLRX).
The analyst comments "We remain Buy Rated on PLRX following their 2Q24 update. The Ph2/3 BEACON-IPF trial remains the key driver for shares over the next 12-18... More
